d 12

Banoxantrone D12 (AQ4N D12) is the deuterium-labeled form of Banoxantrone, a bioreductive agent that can be metabolically converted to AQ4, a stable compound with DNA affinity and topoisomerase II inhibition properties.

Topiramate D12 is a deuterium labeled Topiramate. Topiramate is an agent of broad-spectrum antiepileptic. Topiramate is an antagonist of GluR5 receptor.

Banoxantrone D12 (AQ4N D12) dihydrochloride is the deuterium-labeled Banoxantrone. Banoxantrone is a bioreductive agent that can be reduced to a stable, DNA-affinity compound AQ4, which is a topoisomerase II inhibitor.

3-Hydroxyoctanoic Acid-d12 is the deuterated analog of 3-Hydroxyoctanoic Acid.

Chrysene-d12 is a deuterated compound of Chrysene. Chrysene has a CAS number of 218-01-9. Chrysene is a high molecular weight (HMW), polycyclic aromatic hydrocarbon (PAH).

Perylene-d12 is a deuterated compound of Perylene. Perylene has a CAS number of 198-55-0.

Chrysene-d12 (Standard) is the standard substance of Chrysene-d12, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Chrysene-d12 is a deuterated compound of Chrysene. Chrysene has a CAS number of 218-01-9. Chrysene is a high molecular weight (HMW), polycyclic aromatic hydrocarbon (PAH).

Perylene-d12 (Standard) is the standard substance of Perylene-d12, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Perylene-d12 is a deuterated compound of Perylene. Perylene has a CAS number of 198-55-0.

Vancomycin-d12 TFA is a deuterated compound of Vancomycin TFA. Vancomycin TFA has a CAS number of 1404-90-6. Vancomycin is an antibiotic used to treat serious bacterial infections by stopping the growth of bacteria.

Tetramethylpyrazine-d12 is a deuterated compound of Tetramethylpyrazine. Tetramethylpyrazine has a CAS number of 1124-11-4. Tetramethylpyrazine (ligustrazine, TMP), a natural compound isolated from Chinese herbal medicine Ligusticum wallichii (Chuan Xiong) shows anti-inflammation, antioxidant, antiplatelet, and antiapoptosis activities.

D-(+)-Trehalose-13C12 is an isotopic label of D-(+)-Trehalose, enriched with 13C. This compound is pervasively found and often employed as a food ingredient and a shape-forming agent for active molecules.

KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.

N1,N12-Diacetylspermine-d6 (DiAcSpm-d6) is the deuterated form of N1,N12-Diacetylspermine.

Exatecanintermediate 12-d5 is the deuterium-labeled version of Exatecanintermediate 12. Exatecan intermediate 12 serves as an intermediate in synthesizing the ADC toxin Exatecan, which is utilized in preparing ADC compounds.

18-Hydroxycorticosterone-d4 is a deuterated compound of 18-Hydroxycorticosterone. 18-Hydroxycorticosterone has a CAS number of 561-65-9. 18-Hydroxycorticosterone is a corticosteroid and corticosterone derivative, which can lead to serious electrolyte imbalances.

Benzo[k]fluoranthene-d12 is a deuterated compound of Benzo[k]fluoranthene. Benzo[k]fluoranthene has a CAS number of 207-08-9.

2-deoxy-D-Glucose-13C6is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.32-deoxy-D-Glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg/ml.4,5In vivo, 2-deoxy-D-glucose (500 mg/kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel .6 1.Kang, H.T., and Hwang, E.S.2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimeticLife Sci.78(12)1392-1399(2006) 2.Aft, R.L., Zhang, F.W., and Gius, D.Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell deathBr. J. Cancer87(7)805-812(2002) 3.Ralser, M., Wamelink, M.M., Struys, E.A., et al.A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growthProc. Natl. Acad. Sci. USA105(46)17807-17811(2008) 4.Liu, H., Savaraj, N., Priebe, W., et al.Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C)Biochem. Pharmacol.64(12)1745-1751(2002) 5.Zhang, X.D., Deslandes, E., Villedieu, M., et al.Effect of 2-deoxy-D-glucose on various malignant cell lines in vitroAnticancer Res.26(5A)3561-3566(2006) 6.Maschek, G., Savaraj, N., Priebe, W., et al.2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res.64(1)31-34(2004)

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy. |1. Masuda, Y., Ishizaki, M., and Shimizu, M. Zonisamide: Pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 4(4), 341-360 (1998).|2. Rock, D.M., Macdonald, R.L., and Taylor, C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3(2), 138-143 (1989).|3. Suzuki, S., Kawakami, K., Nishimura, S., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12(1), 21-27 (1992).|4. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).|5. De Simone, G., Di Fiore, A., Menchise, V., et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15(9), 2315-2320 (2005).|6. Yabe, H., Choudhury, M.E., Kubo, M., et al. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 110(1), 64-68 (2009).